Compare PNR & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNR | NBIX |
|---|---|---|
| Founded | 1966 | 1992 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 13.2B |
| IPO Year | 2003 | 1996 |
| Metric | PNR | NBIX |
|---|---|---|
| Price | $90.40 | $128.58 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 22 |
| Target Price | $115.79 | ★ $180.36 |
| AVG Volume (30 Days) | ★ 1.2M | 906.6K |
| Earning Date | 04-21-2026 | 05-04-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | 5.88 | ★ 41.95 |
| EPS | 3.96 | ★ 4.67 |
| Revenue | N/A | ★ $161,626,000.00 |
| Revenue This Year | $4.24 | $22.85 |
| Revenue Next Year | $4.85 | $10.36 |
| P/E Ratio | ★ $22.86 | $28.21 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $77.71 | $92.32 |
| 52 Week High | $113.95 | $160.18 |
| Indicator | PNR | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 51.62 | 45.23 |
| Support Level | $83.60 | $124.09 |
| Resistance Level | $105.10 | $136.74 |
| Average True Range (ATR) | 2.30 | 4.22 |
| MACD | 0.96 | 0.16 |
| Stochastic Oscillator | 81.69 | 40.54 |
Pentair is a global leader in the water treatment industry, with 10,000 employees and a presence in 25 countries. Its business is organized into three segments: pool, water technologies, and flow. The company offers a wide range of water solutions, including energy-efficient swimming pool equipment, filtration solutions, and commercial and industrial pumps. Pentair generated approximately $4.2 billion in revenue in 2025.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.